AKINORI YODA

ヨダアキノリ | AKINORI YODA

Affiliation and department：

Research field (1)： Pathobiochemistry

Research keywords (2)：キナーゼ , kinase

Research theme for competitive and other funds (12)：

2022 - 2025 PDX models of rare hematopoietic malignancies for novel cancer therapies
2019 - 2024 comprehensive studies on the molecular basis of early development and clonal evolution in cancer using advanced genomics.
2019 - 2022 Development of diagnosis and treatment of novel drug targets using refractory leukemia models
2019 - 2021 Cancer immunotherapy targeting neo-self antigens in splicing factor mutated cells
2005 - 2009 Molecular mechanism of DNA damage-induced responses and its failure by carcinogenesis

Show all

Papers (46)：

Takuro Kameda, Kotaro Shide, Ayako Kamiunten, Yasunori Kogure, Daisuke Morishita, Junji Koya, Yuki Tahira, Keiichi Akizuki, Takako Yokomizo-Nakano, Sho Kubota, et al. CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. Communications Biology. 2022. 5. 1
戚星星, Yoshizatoi Testuichi, 南谷泰仁, Nakagawa Masahiro M., 森拓人, 昆彩奈, 依田成玄, 越智陽太郎, 竹田淳恵, 佐伯龍之介, et al. Mis-splicing due to somatic U2AF2 mutations in myeloid neoplasms(和訳中). 日本癌学会総会記事. 2022. 81回. E-1065
Qi Xingxing, Yoshizatoi Tetuichi, 南谷泰仁, Nakagawa Masahiro M., 森拓人, 昆彩奈, 依田成玄, 越智陽太郎, 竹田淳恵, 佐伯龍之介, et al. Mis-splicing due to somatic U2AF2 mutations in myeloid neoplasms(和訳中). 日本癌学会総会記事. 2022. 81回. P-1255
依田成玄, 森下大輔, 越智陽太郎, 水谷明生, 森拓人, 竹田淳恵, 戸崎浩和, 佐藤義彦, 南谷泰仁, 牧島秀樹, et al. 骨髄性腫瘍を標的とした新規スプライシングモジュレーターCTX-712の開発(CTX-712, a novel splicing modulator targeting myeloid neoplasms). 日本癌学会総会記事. 2022. 81回. E-2027
中川正宏, 稲垣良作, 南谷泰仁, 佐伯龍之介, 越智陽太郎, 竹田淳恵, 趙蘭英, 威星星, 依田成玄, 昆彩奈, et al. 単一細胞マルチオミクス解析によるクローン性造血の病態解明(Distinct pathogenesis of clonal hematopoiesis revealed by single-cell multi-omics sequencing). 日本癌学会総会記事. 2022. 81回. IS8-6

ｍore...

MISC (65)：

June Takeda, Kenichi Yoshida, Masahiro M. Nakagawa, Yasuhito Nannya, Akinori Yoda, Ryunosuke Saiki, Yotaro Ochi, Lanying Zhao, Rurika Okuda, Xingxing Qi, et al. Amplified EPOR/JAK2 genes definea unique subtype of acute erythroid leukemia. CANCER RESEARCH. 2022. 82. 12
June Takeda, Kenichi Yoshida, Masahiro Marshall Nakagawa, Yasuhito Nannya, Akinori Yoda, Daisuke Morishita, Ryunosuke Saiki, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, et al. EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. BLOOD. 2021. 138
Masahiro Nakagawa, Ryosaku Inagaki, Yasuhito Nannya, Lanying Zhao, Yotaro Ochi, June Takeda, Xingxing Qi, Akinori Yoda, Ayana Kon, Nobuyuki Kakiuchi, et al. Early Clonal evolution of myeloid malignancies. CANCER SCIENCE. 2021. 112. 969-969
June Takeda, Kenichi Yoshida, Akinori Yoda, Yasuhito Nannya, Masahiro Nakagawa, Yotaro Ochi, Ayana Kon, Tetsuichi Yoshizato, Yusuke Shiozawa, Yuichi Shiraishi, et al. JAK STAT Pathway is a Promising Therapeutic target in Acute Erythroid Leukemia. CANCER SCIENCE. 2021. 112. 453-453
Akinori Yoda, Daisuke Morishita, Akio Mizutani, Yotaro Ochi, Hirokazu Tozaki, Yoshihiko Satoh, June Takeda, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, et al. CTX-712, a novel CLK inhibitor targeting myeloid neoplasms with SRSF2 mutation. CANCER SCIENCE. 2021. 112. 250-250

ｍore...

Professional career (2)：

修士(理学)(東京大学)
博士(医学)(大阪大学)

Work history (1)：

Kobe University Graduate School of Medicine, Faculty of Medical Sciences, KOBE University Graduate School of Medicine Assistant Professor

Association Membership(s) (2)：

日本血液学会 , 日本癌学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page